ArticleFrontiers in endocrinology2026
Identification of differentially expressed plasma small extracellular vesicles miRNAs as biomarkers for type 2 diabetes.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence of Type 2 Diabetes (T2D) has increased over the years. However, the current diagnostic markers such as fasting blood glucose and HbA1c come with certain limitations. Hence, there is a need for a more robust minimally invasive biomarker. This study aimed to identify sets of dysregulated miRNAs in plasma small extracellular vesicles (sEVs) as biomarkers for T2D diagnosis. Methods: This study was part of the Rice Intervention for Chronic Health (RICH) trial. Plasma sEVs were isolated from T2D and control subjects and characterized. The sEVs-miRNAs expressions were compared using next generation sequencing and validated using digital PCR. Bioinformatic analyses were performed to study the roles of dysregulated miRNAs. Plasma proteins were profiled to study the systemically dysregulated T2D pathways. Results: The levels of miR-142-3p and miR-454-3p were increased in plasma sEVs of T2D subjects. Among a subgroup of T2D subjects in whom glycemic control improved (n = 13), these two upregulated miRNAs also decreased. The combination of sEVs-miR-142-3p, waist circumference, and BMI demonstrated high diagnostic values (AUC-ROC=0.985, Conclusion: This study identified the potential of sEV-miR-142-3p as biomarkers for T2D diagnosis when used in combination with waist circumference and BMI. This study provided preliminary evidence of sEVs-miRNAs in future clinical use for T2D management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.